Absci (ABSI) Receivables (2020 - 2026)
Absci (ABSI) posted Receivables of $100000.0 for Q1 2026, down 90.0% sequentially from $1.0 million in Q3 2025, and down 92.77% YoY from $1.4 million in Q1 2025.
Analysis
Absci (ABSI) Receivables (2020 - 2026) Analysis & Trends
Absci has reported Receivables for 7 years, with the latest figure at $100000.0 in Q1 2026.
- Quarterly Receivables fell 92.77% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100000.0 (down 92.77% YoY) and the FY2023 annual result came in at $2.2 million, up 41.23% from the prior year.
- Receivables slipped to $100000.0 in Q1 2026 per ABSI's latest filing, from $1.0 million in the prior quarter.
- Over five years, Receivables peaked at $3.2 million in Q2 2023 and troughed at $42000.0 in Q1 2024.
- A 5-year average of $947466.7 and a median of $800000.0 in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables tumbled 98.61% in 2024, then jumped 3195.24% in 2025.
- Over 5 years, Receivables stood at $1.1 million in 2022, then soared by 99.0% to $2.2 million in 2023, then plunged by 31.48% to $1.5 million in 2024, then plunged by 33.33% to $1.0 million in 2025, then sank by 90.0% to $100000.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $100000.0, $1.0 million, and $700000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Absci | 1.40 Bn | 1.19 Bn | - | 300,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 15.70 Mn |
| Mar 31, 2025 | 16.38 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 16.50 Mn |
| Jun 30, 2024 | 15.04 Mn |
| Mar 31, 2024 | 15.04 Mn |
| Dec 31, 2023 | 17.19 Mn |
| Sep 30, 2023 | 15.80 Mn |
| Jun 30, 2023 | 18.16 Mn |
| Mar 31, 2023 | 16.33 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 210,000.00 |
| Jun 30, 2022 | 310,000.00 |
| Mar 31, 2022 | 350,000.00 |
| Dec 31, 2021 | 600,000.00 |
| Sep 30, 2021 | 714,000.00 |
| Jun 30, 2021 | 545,000.00 |